Valbiotis SA (ENXTPA: ALVAL)
Health Care · Biotechnology · FR
€0.56
+0.36% today · -24.9% 1Y
Valbiotis SA (ENXTPA: ALVAL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $14.70M and employs 50 people.
Over the last twelve months the share price has lost 24.9%, trading between 0.49 and 1.30.
Tweenvest scores Valbiotis SA across four factors: quality 35/100, value 51/100, growth 100/100. Its strongest factor is growth.
ALVAL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $14.70M
- Revenue (TTM)
- $1.53M
- P/E
- —
- EPS
- —
- Dividend yield
- —
- Beta (5Y)
- -0.14
- 52-week high
- €1.30
- 52-week low
- €0.49
- Avg volume (3M)
- —
- Shares outstanding
- 23.66M
- Employees
- 50
- Next earnings
- —
About Valbiotis SA
Valbiotis SA is a French company, established in 2014 and headquartered in Périgny, that specializes in the research and development of nutritional health products. Its primary focus is on preventing and managing metabolic and cardiovascular diseases. The company's pipeline includes several key candidates: TOTUM-63, currently in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, undergoing Phase II trials to address hypercholesterolemia; and TOTUM-854, which is in Phase II/III clinical development for arterial hypertension. Additionally, Valbiotis is developing TOTUM-448 to treat non-alcoholic fatty liver disease. The company maintains a strategic partnership with Nestlé Health Science.
- ISIN
- FR0013254851
- Founded
- 2014
- Listed since
- Jun 7, 2017
- Exchange
- Euronext Paris
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Xcell Therapeutics Inc.KOSDAQ: A373110 | $15.16M | ₩1,169.00 | +9.87% |
| Read-Gene S.A.WSE: RDG | $15.06M | zł4.96 | -1.59% |
| Dyadic International, Inc.NasdaqCM: DYAI | $14.98M | $0.41 | -7.43% |
| SenzaGen ABOM: SENZA | $14.97M | Skr4.56 | +1.10% |
| Poongjeon Pharmacy CO.,LTD.KOSDAQ: A298060 | $14.56M | ₩2,195.00 | -5.39% |
| Actuate Therapeutics, Inc.NasdaqGM: ACTU | $14.53M | $0.61 | -0.85% |
| Initiator Pharma A/SOM: INIT | $14.45M | Skr2.09 | +16.11% |
| FunPep Company LimitedTSE: 4881 | $14.44M | ¥45.00 | +2.27% |
Figures last refreshed Oct 18, 2026.